Stevan Shaw

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker et al. · Annals of the Rheumatic Diseases · 2017 · 259 citations · Full text

Medicine, Immunology, Pharmacology +17

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Ralph Adams, Asher Maroof, Terry Baker et al. · Frontiers in Immunology · 2020 · 193 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Sophie Glatt, Gregor B. E. Jemec, Seth Forman et al. · JAMA Dermatology · 2021 · 167 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Sophie Glatt, Eric Helmer, Birgit Haier et al. · British Journal of Clinical Pharmacology · 2016 · 144 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Interleukin-6 Contributes to Inflammation and Remodeling in a Model of Adenosine Mediated Lung Injury

Mesias Pedroza, Daniel J. Schneider, Harry Karmouty‐Quintana et al. · PLoS ONE · 2011 · 122 citations · Full text

Veterinary Medicine, Immunology, Pathobiology +17